Mapping the landscape of ovarian metastases of gastric cancer: insights, trends, and emerging perspectives
Gastric cancer (GC) has poor prognosis due to distant metastasis with ovarian metastasis (OM) occurring in 5-10% of female patients and survival limited to 7-14 months. No standard treatment exists. This review analyzes global research and trends in OM management. Publications on OM in GC (1991-2024) were retrieved from the Web of Science Core Collection. Bibliometric analysis of 324 articles was performed using CiteSpace and VOSviewer. Three main themes emerged: (1) diagnosis and pathology characteristics of OM, (2) treatment and management, and (3) clinical features in special populations, such as pregnancy. Research hotspots include multidisciplinary treatment (MDT), diagnostic tumor markers (e.g., CA125, CA19-9, and carcinoembryonic antigen (CEA)), imaging (e.g., MRI, ultrasound), and novel approaches such as immunotherapy and targeted therapy (Microsatellite Instability-High (MSI - H), Tumor Mutational Burden-High (TMB - H). Future directions call for multicenter clinical trials and interdisciplinary collaboration to improve patient outcomes.